Dove Medical Press Web viewSupplementary Figure 1 Expression of APLN in rat hippocampal neurons with...
3
Supplementary materials Supplementary Figure 1 Expression of APLN in rat hippocampal neurons with kindled epilepsy Rats with kindled epilepsy were treated with APLN shRNA, APLN overexpression vector, and miR-182 agomir, injected via the tail. Rats included in the control group were treated with saline and Lipofectamine 2000. APLN expression in the hippocampal neurons were examined by qRT-PCT. **** P < 0.0001. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Transcript of Dove Medical Press Web viewSupplementary Figure 1 Expression of APLN in rat hippocampal neurons with...
Supplementary materials
Supplementary Figure 1 Expression of APLN in rat hippocampal neurons with kindled epilepsy
Rats with kindled epilepsy were treated with APLN shRNA, APLN overexpression vector, and miR-182
agomir, injected via the tail. Rats included in the control group were treated with saline and
Lipofectamine 2000. APLN expression in the hippocampal neurons were examined by qRT-PCT. ****P <
0.0001.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Supplementary Figure 2 Expression of apoptosis-associated proteins, mGluR1, and p-AKT levels in
the hippocampal neurons from rats with epilepsy
Rats with kindled epilepsy were treated with APLN shRNA, APLN overexpression vector, and miR-182
agomir, injected via the tail. Rats included in the control group were treated with saline and
Lipofectamine 2000. Protein expression was examined by Western blotting. β-actin was used as a loading
control. A. Western blotting was performed to examine the protein levels of mGluR1, p-AKT, Bax,
caspase-3, and Bcl-2. Statistical results of mGluR1 expression (B), p-AKT level (C), Bax expression (D),
caspase-3 expression (E), and Bcl-2 expression (F) in different groups. ns, non-significant; ***P < 0.001,
****P < 0.0001.
19
20
21
22
23
24
25
26
27
28
Supplementary Figure 3 Target gene prediction for miR-182
29
30
